Date:9/24/2009

2008 Sales $42,894,355 $33,459,609 Cost of sales 21,516,065 18,802,225 Gross profit 21,378,290 14,657,384 Operating expenses Selling expenses 7,825,939 4,725,480 General and administrative expenses 3,491,804 2,132,438 Research and development 343,952 230,745 Total operating expenses 11,661,695 7,088,663 Income from operations 9,716,595 7,568,721 Other income (expenses): Interest income 357,343 -- Interest expense (95,880) (368,113) Impairment loss on intangible assets (431,344) -- Total other income (expenses) (169,881) (368,113) Income before provision for income tax 9,546,714 7,200,608 Provision for income tax 1,639,104 1,229,300 Net income 7,907,610 5,971,308 Other comprehensive income Foreign currency translation adjustment 73,506 2,044,766 Comprehensive income $7,981,116 $8,016,074 Basic earnings per share $0.41 $0.38 Diluted earnings per share $0.32 $0.31 Weighted average number of common shares outstanding: Basic 15,937,411 14,511,717 Diluted 24,805,281 19,127,853

Consolidated Statements of Cash Flows

                                                   For the Years Ended June 30,
                    
'/>"/>
SOURCE  Tianyin Pharmaceutical Co., Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 
Related biology technology :

1. Tianyin Pharmaceutical, Inc. to Host 2008 Second Quarter Earnings Conference Call on Thursday, February 14, 2008 at 4:15 p.m. EST
2. Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results
3. Tianyin Pharmaceutical Appoints Three New Independent Board Members
4. Tianyin Pharmaceutical Announces SFDA Approval to Market Azithromycin Dispersible Tablets
5. Tianyin Pharmaceutical to Present at the Brean Murray All-Cap All-China Conference in New York City on May 20, 2008 at 10:15 a.m. EDT
6. Tianyin Pharmaceutical Co., Inc. to Present at Rodman & Renshaw Annual Global Investment Conference in New York City on November 11, 2008 at 12:00 p.m. EST
7. Tianyin Pharmaceutical Co., Inc. Announces First Quarter 2009 Financial Results
8. Tianyin Pharmaceutical Co., Inc. Implements New Sales and Marketing Strategy to Drive Revenue Growth
9. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Wednesday, February 18, 2009 at 8:45 a.m. EST
10. Tianyin Pharmaceutical Co., Inc. Adopts New Sales Strategy for Azithromycin Dispersible Tablets
11. Tianyin Pharmaceutical Co., Inc. Announces Cash Dividend to Common Stockholders